Annals of Epidemiology
Volume 19, Issue 2 , Pages 96-102 , February 2009

Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy

  • Gary G. Schwartz, PhD, MPH, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Gary G. Schwartz, PhD, MPH, PhD, Departments of Cancer Biology and Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC 27157. Tel.: 336-716-7446; fax: 336-716-5687.

References 

  1. de Vries , Soerjomataram I, Houterman S, Louwman MW, Coebergh JW. Decreased risk of prostate cancer after skin cancer diagnosis: A protective role of ultraviolet radiation?. Am J Epidemiol. 2007;165:966–972
  2. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D gene polymorphisms and risk of advanced prostate cancer. Cancer Res. 2005;65:5470–5479
  3. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1990–1999
  4. Schwartz GG. The “Cocaine Blues” and other problems in epidemiologic studies of vitamin D and cancer. Nutr Rev. 2007;65:S75–S76
  5. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dialysis. 2005;18:276–289
  6. In:  Kurihara M,  Aoki K,  Hismamichi S editor. Cancer Mortality Statistics in the World, 1950–1985. Nagoya, Japan: University of Nagoya Press; 1989;
  7. Yatani R, Chigusa I, Akazaki K, Stermmerman G, Welsh R, Correa P. Geographic pathology of latent prostate carcinoma. Int J Cancer. 1984;29:611–616
  8. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 patients treated by external beam radiation therapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  9. Pound CR, Parti AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  10. Sharifi N, Gulley JL, Dahut WI. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–244
  11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med. 2004;351:1502–1512
  12. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer (Hypothesis)?. Anticancer Res. 1990;10:1307–1311
  13. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer. 1992;70:2861–2869
  14. Schwartz GG, Hanchette CL. UV, latitude, and prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control. 2006;17:1091–1101
  15. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α, 25-dihydroxyvitamin D3. Cancer Res. 1992;52:515–520
  16. Moreno J, Krishnan AV, Feldeman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Bol Biol. 2005;97:31–36
  17. Schwartz GG, Wang M-H, Zhang M, Singh RK, Siegal GP. 1α, 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 1997;6:727–732
  18. Sung V, Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol. 2000;164:133–143
  19. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang S-H, Block NL, et al. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25-Dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev. 1999;8:241–248
  20. Bao BY, Yeh SD, Lee YF. 1α,25-Dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis. 2006;27:32–42
  21. Bao Y-B, Yao J, Lee Y-F. 1α-Dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 2007;27:1883–1889
  22. Haddad JG, Hahn TJ. Natural and synthetic sources of circulating 25-Hydroxyvitamin D in man. Nature. 1973;244:525–527
  23. Holick MF. Photobiology of vitamin D. In:  Feldman D,  Gloriexux FH,  Pike JW editor. Vitamin D. 1st ed.. San Diego, CA: Academic Press; 1997;p. 33–39
  24. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;19:266–281
  25. Hansen CM, Binderup L, Hamberg KJ, Carlberg C. Vitamin D and cancer: Effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosc. 2001;6:D820–D848
  26. Hewison M, Burke F, Evans KN, Lammas DA, Sansum DM, Liu P, et al. Extra-renal 25-Hydroxyvitamin D3–1α-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103:316–321
  27. Chesney RW, Rosen JF, Hanstra AJ, Smith C, Mahaffey K, DeLuca HF. Absence of seasonal variations in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. J Clin Endocrinol Metab. 1981;53:139–143
  28. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-Dihydroxyvitamin D3 from 25-Hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 1998;7:391–395
  29. Barreto A, Schwartz GG, Woodrugg R, Cramer SD. 25-Hydroxyvitamin D3, the prohormonal form of 1,25-Dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev. 2000;9:265–270
  30. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, et al. The prostate 25-Hydroxyvitamin D-1α-Hydroxylase is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis. 2004;25:967–971
  31. Haussler MR, Jurutka PW, Hseih JC, Thompson PD, Selznick SH, Hausller CA, et al. New understanding of the molecular mechanism of receptor-mediated genomic actions of vitamin D hormone. Bone. 1995;17:33S–38S
  32. Zhuang S-H, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cells. Mol Cell Endocrinol. 1997;126:83–90
  33. Krill D, De Flavia P, Dhir R, Luo J, Becich MJ, Lehman E, et al. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem. 2001;82:566–572
  34. Miller GJ, Stapleton GE, Hedlund TE, Moffatt KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res. 1995;1:997–1003
  35. Kivineva M, Bläuer M, Syvälä H, Tammela T. Tuohimaa. Localization of 1,25-Dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol. 1998;66:121–127
  36. Blutt SE, Weigel NL. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999;221:89–98
  37. Miller GJ. Vitamin D and prostate cancer: Biological interactions and clinical potentials. Cancer Metastasis Rev. 1998;17:353–360
  38. Hsu JY, Feldman D, McNeal JE, Peehl DM. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001;61:2852–2856
  39. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, et al. 25-Hydroxyvitamin D-1-alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol. 2002;81:135–140
  40. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. The use of 25-Hydroxyvitamin D3 and 19-nor-1,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res. 2000;6:901–908
  41. Abe E, Miyamura C, Sakagami H, Takeda M, Konno K, Yamazaki T, et al. Differentiation of mouse myeloid leukemia cellsinduced by 1α, 25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1981;78:4990–4994
  42. Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, et al. 1α,25—Dihydroxyvitamin D3 and 1 α-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci U S A. 1983;80:201–204
  43. Tobler A, Koeffler HP. Differentiation of human acute myelogencres leukemia cells: Therapeutic possibilities. Acta Haematol. 1987;78(Suppl 1):127–135
  44. Muindi JR, Peng Y, Potter P, Hershberger PA, Tauch JS, Capozilli MJ, et al. Pharmacokinetics of high-dose oral calcitriol; Results from a phase I trial of calcitriol and paclitaxel. Clin Pharmaocol Ther.s. 2002;72:648–659
  45. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25-Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993;132:1952–1960
  46. Schwartz GG, Oeler T, Uskokovic M, Bahnson RR. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res. 1994;14:1077–1081
  47. Schwartz GG, Hill CC, Oeler T, Becich MJ, Bahnson RR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology. 1995;46:365–369
  48. Vijayakumar S, Mehta RR, Boerner PS, Packianathan S, Mehta RG. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J. 2005;11:362–373
  49. Osborn JL, Schwartz GG, Smith DC, Bahnson RR, Day R, Trump DL. Phase II trial of oral 1,25-Dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urologic Oncol. 1995;1:195–198
  50. Liu G, Oettel K, Ripple G, et al. Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer. Clinical Cancer Res. 2002;8:2820–2827
  51. Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. Cancer Metast Rev. 2002;21:147–158
  52. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 Dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006;106:2136–2142
  53. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005;11:7794–7799
  54. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators. J Clin Oncol. 2007;25:669–674
  55. Novacea Press Release. November 05, 2007. Novacea halts ASCENT-2 trial in advanced prostate cancer. Available at: www.novacea.com/610.asp?id=136&;nav=news. Accessed April 17, 2008.
  56. Beer TM. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int. 2005;96:508–513
  57. Brawer MK. Recent progress in the treatment of advanced prostate cancer with intermittent dose-intense calcitriol. Rev Urol. 2007;9:1–8
  58. Schwartz GG, Hall MC, Patton S, Lee WR, Stindt D, Lovato J, et al. A Phase I/II trial of 19-nor-1α,25-Dihydroxyvitamin D2 (paricalcitol) in advanced androgen insensitive prostate cancer. Clin Cancer Res. 2005;11:8680–8685
  59. Schnieder A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology. 2005;146:1727–1736
  60. Saad F, Clarke N, Columbel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol. 2006;49:429–440
  61. Schwartz GG. Prostate cancer, serum parathyroid hormone and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev. 2008;17:478–483
  62. Andress D. Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease. Drugs. 2007;67:1999–2012
  63. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159:2035–2040
  64. Woo TCS, Jamieson J, Chander S, Vieth R. Pilot study: Potential role of vitamin D (choecalciferol) in patients with PSA replapse after definitive therapy. Nutr Cancer. 2005;51:32–36
  65. Beer TM, Eilers KM, Garzotto M, Hsieh Y-C, Mori M. Quality of life and pain relief during treatment with calcitriol and docetazel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer. 2004;100:758–763
  66. Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol. 2000;163:187–190
  67. Petrioli R, Pascuccu A, Francinin E, Marsili S, Sciandiviasci A, De Rubertis G, et al. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007;100:775–779
  68. Mould JW, Ward JF. Management of the patient with a rising PSA alone. Hematol Oncol Clin N Am. 2006;20:897–908
  69. Farhan W, Wahala K, Cross HS. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol. 2003;84:432–429

PII: S1047-2797(08)00062-8

doi: 10.1016/j.annepidem.2008.03.007

Annals of Epidemiology
Volume 19, Issue 2 , Pages 96-102 , February 2009

Article Tools

* Image Usage & Resolution